Macular degeneration
MONDO:0003004Loss of vision in the central portion of the retina (macula), secondary to retinal degeneration.
Also known as: macula lutea retinal degeneration, macula retinal degeneration, retinal degeneration of macula lutea
436 clinical trials for this condition and its sub-types, 212 tagged with Macular degeneration itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Macular degeneration
-
Degeneration of macula and posterior pole 0 trials · 354 incl. sub-types
6 sub-types
- Age-related macular degeneration 190 trials · 334 incl. sub-types Sub-types →
- Preretinal fibrosis 21 trials
- Retinal drusen 0 trials · 2 incl. sub-types Sub-types →
- Toxic maculopathy 2 trials
- Hole retinal cyst 1 trial
- Cystoid macular retinal degeneration 0 trials
-
Stargardt disease 33 trials · 34 incl. sub-types
4 sub-types
- Severe early-childhood-onset retinal dystrophy 8 trials
- Stargardt disease 3 3 trials
- Stargardt disease 4 0 trials
- Stargardt disease 5 0 trials
-
Macular retinal edema 19 trials · 27 incl. sub-types
1 sub-type
- Cystoid macular edema 9 trials
-
Vitelliform macular dystrophy 6 trials · 10 incl. sub-types
2 sub-types
-
Autosomal recessive bestrophinopathy 2 trials
-
Isolated macular dystrophy 0 trials
-
Macular degeneration, early-onset 0 trials
-
Occult macular dystrophy 0 trials
-
Patterned macular dystrophy 0 trials
3 sub-types
- Patterned macular dystrophy 1 0 trials
- Patterned macular dystrophy 2 0 trials
- Patterned macular dystrophy 3 0 trials
Most studied deeper sub-types
-
New eye injection targets Blindness-Causing lesions
Disease control Stopped earlyThis early-stage study tests the safety of an experimental drug called RO7669330, given as an injection into the eye, for people with geographic atrophy (GA) due to age-related macular degeneration (AMD). The study involves 27 participants and will monitor side effects and eye he…
Phase 1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Experimental gene injection targets dry AMD
Disease control Stopped earlyThis early-stage trial tested a gene therapy called GT005 for dry age-related macular degeneration (AMD), a leading cause of vision loss. The therapy delivers a working gene to the retina via a single injection. The study enrolled 56 people and focused on safety and dosing, but w…
Phase 1/2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New eye scanner software could sharpen diagnosis of macular degeneration
Diagnosis Stopped earlyThis study tested a new software called AngioScan, used with an already-approved eye camera, to see if it can take better pictures of the back of the eye. Researchers looked at 150 patients with retinal problems like macular degeneration. The goal was to find out if the software …
Sponsor: University of California, Los Angeles • Aim: Diagnosis
Last updated Jun 27, 2026 12:10 UTC
-
Tiny genetic clues may unlock eye disease mysteries
Knowledge-focused Stopped earlyThis study looked at people with cone disorders, a type of inherited eye disease that affects color vision and sharp sight. Researchers analyzed genetic changes of unknown significance to see if they cause disease. The goal was to improve genetic diagnosis, not to test a treatmen…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC